Cytosorbents (CTSO) vs IRIDEX (IRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IRIDEX (IRIX) has outperformed Cytosorbents (CTSO) over the past year, losing 17.6% versus a loss of 80.9%. Over five years, IRIX leads with a -87.9% price change compared with -96.8% for CTSO. IRIDEX is the larger company by market cap ($15.8 million vs $11.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | IRIX |
|---|---|---|
| Share price | $3.73 | $0.898 |
| Market cap | $11.75M | $15.77M |
| 1-day change | -3.62% | +2.24% |
| YTD return | -70.81% | -21.23% |
| 1-year return | -80.87% | -17.61% |
| 5-year return | -96.82% | -87.88% |
| EPS (TTM) | $-5.80 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.72 | $1.65 |
| 52-week low | $3.66 | $0.61 |
| Distance from 52-week high | -81.09% | -45.58% |
| Analyst consensus | none | none |
| Avg. price target upside | +1173.46% | +206.24% |
| Average volume | 12.45K | 389.24K |
| Shares outstanding | 3.15M | 17.56M |
| Employees | 129 | 93 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRIX has outperformed CTSO by 63.3 percentage points over the past year.
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Healthcare · Medical Devices · 129 employees
About IRIDEX
IRIX stock →IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Healthcare · Medical Devices · 93 employees
CTSO vs IRIX FAQ
Which is bigger, Cytosorbents or IRIDEX?
IRIDEX (IRIX) is larger, with a market capitalization of $15.77M compared with $11.75M for Cytosorbents (CTSO).
Which stock has performed better over the past year, CTSO or IRIX?
IRIX returned -17.61% over the past 12 months, compared with -80.87% for CTSO (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and IRIDEX in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.